—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BioNTech SE (BNTX) — chart, structure and Closelooknet read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — BioNTech SE

BNTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BioNTech develops immunotherapies, best known for its mRNA-based vaccine against SARS-CoV-2. It also runs a broad oncology pipeline spanning lung, breast, colorectal and other solid tumours, alongside infectious-disease candidates for influenza, tuberculosis and malaria. The company was founded in 2008 and is based in Mainz, Germany.
Where it sits in the stack
BioNTech carries no seat in our Rubin index and no layer assignment there; it belongs to the Healthcare sleeve of our universe rather than the AI build-out stack.
Who it is priced against
Closelooknet's peer group places it with scored Healthcare names based in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names Pfizer, its partner on the COVID vaccine, as a comparison.
Why Closelooknet tracks it
It holds a seat in our Euro-AI 50 index and carries a Closelooknet score, strongest on valuation and weakest on quality; the diary records no quotes or mentions for it so far.
What the diary watches
Whether oncology trial readouts move the pipeline value the market has priced in, and whether the mRNA platform finds use beyond vaccines.

BioNTech SE (BNTX) trades on US exchanges, classified under Healthcare. Constituent of Euro-AI 50.

The Closelooknet company score reads 38/100 composite (momentum 50, quality 34, valuation 51) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelooknet reading that exists for BNTX, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Canaccord, 2026-08-31

The Street on this name

Analyst actions and the latest print for BNTX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Canaccord — target 136 from 142 Target cut to $136 from $142 (+33.2% to spot) 2026-08-31

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against BNTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Versus its index Euro-AI 50 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

Euro-AI 50 · as of 2026-09-25

DayWeekMonth3 months
BNTX−0.7%+2.6%−12.5%+8.0%
Euro-AI 50+0.4%+1.8%−3.7%—

Against the index: 0.8 pts ahead on the week, 8.8 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BNTX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 none reported
  • Share count +0.5% in FY2025 106 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

How it trades on rate days beta 1.38 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How BNTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.38 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), BioNTech SE moved 1.38% on average · correlation 0.28 · higher than 95% of US names
  • Beta, last 3 months 2.59 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.72% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.81% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sector × region Health care in US: +1.8% week · −1.3% month · +6.9% quarter · +12.0% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25

FAQ · from the current data · as of 2026-09-26

Quick answers

What is BioNTech SE (BNTX)?

BioNTech SE trades as BNTX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is BNTX in a Closelooknet index?

Yes — BioNTech SE is a constituent of Euro-AI 50, as of 2026-09-26.

What is BioNTech SE's Closelooknet composite score?

38 out of 100, with momentum 50, quality 34 and valuation 51 sub-scores, as of 2026-09-26. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does BNTX trade against its moving averages?

Golden cross: Its 50-day crossed above its 200-day 2 sessions ago — a golden cross, the classic trend-turn-higher. As of 2026-09-24 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is BNTX doing against its Closelooknet index?

Over the past month BioNTech SE is −12.5% against −3.7% for the Euro-AI 50 — 8.8 points behind its index, as of 2026-09-25. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

What does BioNTech SE do?

BioNTech develops immunotherapies, best known for its mRNA-based vaccine against SARS-CoV-2. It also runs a broad oncology pipeline spanning lung, breast, colorectal and other solid tumours, alongside infectious-disease candidates for influenza, tuberculosis and malaria. The company was founded in 2008 and is based in Mainz, Germany. Closelooknet's peer group places it with scored Healthcare names based in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names Pfizer, its partner on the COVID vaccine, as a comparison.

Where does BioNTech SE sit in the AI build-out?

BioNTech carries no seat in our Rubin index and no layer assignment there; it belongs to the Healthcare sleeve of our universe rather than the AI build-out stack. It holds a seat in our Euro-AI 50 index and carries a Closelooknet score, strongest on valuation and weakest on quality; the diary records no quotes or mentions for it so far.

Does BioNTech SE pay a dividend?

No cash distribution shows in BioNTech SE’s price series over the last three years. The share count rose 0.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

How does BioNTech SE trade when bond yields rise?

Over the past year BioNTech SE had a beta of 1.38 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 95% of US names. On the 10 sessions in which long bonds fell most it moved −0.72% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What has Wall Street done on BioNTech SE recently?

The most recent analyst action on BioNTech SE on the Closelooknet wire is a price target by Canaccord on 2026-08-31 (target 136 from 142). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BNTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.